Sakar Healthcare

What Sakar Healthcare does

Sakar Healthcare Ltd is an Ahmedabad-based, publicly listed (NSE: SAKAR) pharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in 2004 by Sanjay Shah and Rita Shah. The company operates two manufacturing units in Gujarat — a general facility at Changodar and an EU GMP-approved oncology facility at Bavla — producing liquid orals, cephalosporin tablets/capsules/dry powder injections, liquid injectables (SVP in ampoules and vials), and lyophilized injections, with specialized capacity for HPAPI handling and oncology formulations including oral solids, injectables, lyophilized products, and APIs.

The company's technology stack includes DSIR-recognized R&D, Formulation Development, and Analytical Development laboratories, AI-integrated flow chemistry for API synthesis, lyophilization capacity of 22,000 units per cycle, and high-speed visual inspection at 18,000 units per hour. Product breadth covers 24+ oncology oral solids, 13+ oncology injectables, 21+ oncology APIs, and 40+ general pharmaceutical formulations, with commercial APIs including Gefitinib, Imatinib Mesylate, Cytarabine, and Gemcitabine HCl.

Sakar generates revenue through contract manufacturing fees, technology transfer arrangements, oncology product supply agreements, and licensing deals. The customer base includes multinational pharmaceutical companies (Zydus Lifesciences, Accord-Intas, Torrent, Emcure, Glenmark) for technology transfer and regulated-market supply, with 40 anti-cancer agreements globally and distribution across 38+ countries through 250+ registered brands. A wholly-owned subsidiary, Sakar Oncology, focuses on the anti-cancer API and finished dosage formulation business. FY26 (ended March 31, 2026) revenue was ₹251.74 crore with a 36.91% operating margin, reflecting 41.76% YoY revenue growth and 74% YoY net profit growth.

Name

Sakar Healthcare

Legal name

Sakar Healthcare Ltd

Website

https://sakarhealthcare.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

251–500 employees

Short description

Sakar Healthcare is an EU GMP-approved Indian pharmaceutical CDMO manufacturing oncology and general formulations (oral solids, injectables, lyophilized products, APIs) for multinational pharma partners across 38+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industries

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Pharmaceutical contract manufacturing
• Oncology drug manufacturing
• Lyophilized injection production
• Cephalosporin antibiotic manufacturing
• Active pharmaceutical ingredients

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Contract Manufacturing (CDMO Services): Sakar Healthcare operates as an EU GMP approved Contract Development and Manufacturing Organization (CDMO) for leading multinational pharmaceutical companies. Revenue is generated through manufacturing fees for pharmaceutical products across multiple therapeutic categories including oncology, antibiotics, and general formulations.
2. Product Supply Agreements: Supply of oncology products to partners like Zydus Lifesciences for GCC countries and other emerging markets. With 40 anti-cancer agreements globally, the company generates recurring revenue through product supply contracts.
3. API (Active Pharmaceutical Ingredient) Manufacturing: Manufacturing and supply of oncology APIs including commercial products like Gefitinib, Imatinib Mesylate, Cytarabine, Gemcitabine HCl, and pipeline products like Sunitinib, Afatinib, Axitinib.
4. Licensing and Technology Transfer: Licensing agreements with partners like Algorae Pharmaceuticals for launching generic oncology medicines in international markets (Australia and New Zealand). Revenue from technology transfer and marketing authorizations.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Sakar Healthcare operates as an EU GMP-approved Contract Development and Manufacturing Organization (CDMO) producing pharmaceutical formulations across two main lines: General Products (Oral Liquid Syrups & Suspensions, Cephalosporin Dry Powder Injections, Cephalosporin Oral Solids, Liquid Injectables in Vials & Ampoules, and Lyophilised Injections) and Oncology Products (Oral Solid Dosage, Oral Liquid, Liquid Injection, Lyophilised Injection, and Active Pharmaceutical Ingredients). The company also provides technology transfer, CRAMs services, and licensing arrangements to multinational pharmaceutical firms across 38+ countries.

Product overview

Sakar Healthcare operates as a contract development and manufacturing organization (CDMO) providing end-to-end pharmaceutical manufacturing solutions. The company offers two main product lines: General Pharmaceutical Products including Oral Liquid Syrups and Suspensions, Cephalosporin-based products (Dry Powder Injections, Oral Solids), Liquid Injectables (SVP) in Vials and Ampoules, and EU GMP-approved Lyophilised Injections; and Oncology Products encompassing oral solid dosages (tablets, capsules), oral liquids, liquid injections, lyophilised injections, and Active Pharmaceutical Ingredients (APIs). The company serves as a manufacturing partner for multinational pharmaceutical companies through its CDMO and CRAMs service offerings. The company has signed 40 anti-cancer agreements globally as of May 2026.

Differentiator

Problem solved

Functional benefit

Products and services

• Oral Liquid Syrup & Suspension Oral liquid formulations including syrups and suspensions for therapeutic categories such as analgesics, antipyretics, antibiotics, vitamins, and cough expectorants, manufactured in 10ml to 200ml bottle volumes. Targeted at pharmaceutical company clients and emerging market distribution partners.
• Liquid Injectable (SVP) - Vials & Ampoules EU GMP approved Small Volume Parenteral (SVP) products in ampoules and vials, covering over 43 liquid injectable products across antibiotics, cardiovascular, anti-inflammatory, and other therapeutic categories. For pharmaceutical company partners requiring EU GMP injectable supply.
• Cephalosporin Dry Powder Injections Cephalosporin-based dry powder injectable antibiotics including Ceftriaxone, Cefotaxime, Cefoperazone, Cefazolin, Cefepime, and Ceftazidime in various dosage strengths. Used by hospital and pharma company clients for antibiotic therapy.
• Cephalosporin Oral Solid Oral solid dosage forms including Cephalosporin tablets, capsules, dry syrups, and sachets, comprising over 30 products such as Cefalexin, Cefadroxil, Cefixime, Cefuroxime, and Cefpodoxime. Targeted at antibiotic treatment channels.
• Lyophilised Injections (In Vials) - EU GMP Approved EU GMP approved lyophilized (freeze-dried) injectable products including Gemcitabine, Doxorubicin, Pemetrexed, Bortezomib, Mitomycin, and Azacitidine for oncology treatment. For pharmaceutical partners supplying regulated oncology markets.
• Oncology Oral Solid Dosage Oncology oral solid dosage forms including tablets and capsules covering 24+ molecules such as Abiraterone, Capecitabine, Imatinib, Lapatinib, Lenalidomide, Sorafenib, Sunitinib, and Temozolamide. For oncology treatment channels via pharma partners.
• Oncology Oral Liquid Oncology oral liquid formulations including oral suspensions for drugs such as Capecitabine, Dasatinib, Imatinib, Lenalidomide, Methotrexate, Sunitinib, Tamoxifen Citrate, and Temozolomide. For oncology patients requiring liquid dosage forms.
• Oncology Liquid Injection Oncology liquid injectable products including Carboplatin, Cisplatin, Cytarabine, Docetaxel, Doxorubicin HCl, Gemcitabine, Irinotecan HCl, Leucovorin Calcium, Methotrexate, Oxaliplatin, and Paclitaxel. For hospital and oncology treatment channels.
• Oncology Lyophilised Injection Oncology lyophilized injectable products including Azacitadine, Bendamustine HCl, Bortezomib, Cyclophosphamide, Dactinomycin, Decitabine, Doxorubicin HCl, Doxorubicin HCl Liposome, Gemcitabine HCl, Mitomycin, and Pemetrexed. For oncology hospital and treatment center channels.
• Oncology Active Pharmaceutical Ingredient (API) Commercial and pipeline oncology Active Pharmaceutical Ingredients (APIs) including Gefitinib, Imatinib Mesylate, Cytarabine, Gemcitabine HCl, Capecitabine, Erlotinib, Bortezomib, and Irinotecan HCl. Supplied to formulation partners globally.
• CDMO Services End-to-end Contract Development and Manufacturing Organization (CDMO) services including formulation development, analytical development, technology transfer, and commercial manufacturing for multinational pharmaceutical companies across oncology, antibiotics, and general formulations.
• CRAMs Services Contract Research and Manufacturing Services (CRAMs) covering pharmaceutical development and production for partner companies, supporting both R&D and commercial manufacturing needs.

Quantifiable outcome

• Operating profit margin improved to 36.91%
• +4 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Zydus LifesciencescoreStrategic or Co-development Partner · 24 May 2026Agreement for supply of oncology products across GCC countries and other emerging markets. This partnership marks the company's 40th anti-cancer agreement globally, strengthening international oncology business and expanding execution capabilities in highly regulated markets.
• Accord-IntascoreStrategic or Co-development PartnerOngoing technology transfer projects for oncology products. Partnership supports company's CDMO business expansion and regulatory filings.
• Torrent Pharma (UK & Germany)coreStrategic or Co-development PartnerTechnology transfer partnerships targeting regulated markets including UK and Germany. Company has submitted 33 site variations covering 18 cytotoxic molecules with regulatory partners in these regions.
• Emcure PharmaceuticalscoreStrategic or Co-development PartnerOngoing technology transfer partnership for oncology product development and commercialization.
• Glenmark PharmaceuticalscoreStrategic or Co-development PartnerTechnology transfer partnership for oncology products as part of company's expansion in anti-cancer segment.
• Algorae PharmaceuticalscoreOEM/ Whitelabel/ Licensing PartnerLicensing agreement for launching five generic oncology medicines in Australia and New Zealand, with combined market valued at approximately $10 million per annum. First shipment expected following high-throughput validation trial at Peter MacCallum Cancer Centre, Melbourne.
• Ferring PharmaceuticalminorStrategic or Co-development PartnerMeeting with strategic global team of Ferring Pharmaceutical mentioned in corporate announcements, indicating potential partnership discussions.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Gland Pharma: Gland Pharma is an Indian sterile injectable manufacturer with strong FDA-approved facilities serving global pharma. Closely comparable to Sakar's injectable and lyophilized CDMO business for regulated markets.
• Piramal Pharma Solutions: Piramal's CDMO arm offers end-to-end contract development and manufacturing for oncology, HPAPIs, and sterile injectables across Indian and global sites. Direct competitor to Sakar in oncology CDMO and sterile injectable contract manufacturing.
• Suven Pharmaceuticals: Suven is an Indian CDMO specializing in niche API development and manufacturing, including oncology intermediates. Comparable as a high-quality CDMO serving global pharma with similar technology transfer and supply models.
• Shilpa Medicare: Shilpa operates an oncology-focused API and formulation CDMO with strong development and manufacturing capabilities. Closest direct peer to Sakar in oncology APIs and lyophilized oncology injectables.
• Syngene International: Syngene is India's largest pure-play CDMO offering small molecule and biologics development and manufacturing to global pharma. Overlaps with Sakar's contract development, formulation, and commercial manufacturing services.

Broad incumbents

• Divis Laboratories: Divis is a leading Indian API manufacturer with strong R&D and complex chemistry capabilities across generics and nutraceuticals. Adjacent peer with shared API manufacturing and technology transfer exposure.
• Jubilant Pharmova: Jubilant operates sterile injectables, radiopharma, and CDMO services at global scale including the US Spokane site. Broader portfolio peer with overlapping sterile injectable CDMO and API manufacturing capabilities.
• Aurobindo Pharma: Aurobindo is one of the largest Indian generic manufacturers with significant injectable and API manufacturing capabilities for regulated markets. Broad incumbent with overlapping oncology API and injectable offerings.
• Dr. Reddy's Laboratories: Dr. Reddy's is a major Indian pharma company with global manufacturing, API, and CDMO operations. Provides a broad incumbent benchmark for sterile injectables, oncology, and emerging markets distribution.
• Lupin Pharmaceuticals: Lupin is a large Indian generic drug manufacturer with cephalosporin, injectable, and CDMO exposure through its global manufacturing network. Overlaps with Sakar on cephalosporin formulations and injectable manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sakar Healthcare